Severe

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Condition:   Hypereosinophilic SyndromeInterventions:   Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsulesSponsor:   GlaxoSmithKlineNot yet recruiting – verified July 2016 View full post on ClinicalTrials.gov: asthma | Studies received in the last 14…